“What takes longer to analyze? NEWS2, or a pulse
Post# of 147899
(Total Views: 390)
Posted On: 01/15/2021 12:53:09 PM
“What takes longer to analyze? NEWS2, or a pulse?”
The answer is irrelevant as pulse is not an endpoint in either trial. Change in baseline of SpO2 was a secondary endpoint in the M2M trial and that’s about as simple to calculate as all cause mortality, a secondary endpoint in the S/C trial.
The endpoints for both trials are fairly similar when considering time needed for proper analysis. If the reduction in mortality is stat sig and safety data is available, release it, but investors shouldn’t encourage CYDY to rush the data (yes, they read this board hourly) as the rushed safety data PR for the M2M trial flopped on release so badly that it had to be rereleased for clarity purposes. We don’t need that with the S/C data.
The answer is irrelevant as pulse is not an endpoint in either trial. Change in baseline of SpO2 was a secondary endpoint in the M2M trial and that’s about as simple to calculate as all cause mortality, a secondary endpoint in the S/C trial.
The endpoints for both trials are fairly similar when considering time needed for proper analysis. If the reduction in mortality is stat sig and safety data is available, release it, but investors shouldn’t encourage CYDY to rush the data (yes, they read this board hourly) as the rushed safety data PR for the M2M trial flopped on release so badly that it had to be rereleased for clarity purposes. We don’t need that with the S/C data.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼